Related Experiment Video

Updated: Aug 30, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenetic aspects in treatment of colorectal cancer--an update

Jan Stoehlmacher1, Eray Goekkurt, Heinz Josef Lenz

  • 1GI Oncology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA. lenz@usc.edu

Pharmacogenomics
|November 5, 2003
PubMed

Insights

Pharmacogenomic (PGx) analysis is vital for predicting patient response and toxicity to chemotherapy. Future research and clinical trials will refine PGx markers for personalized cancer treatment.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Genetics

Background:

  • Pharmacogenomic analyses are essential for predicting patient responses to cancer treatments and potential toxicities.
  • Key biological processes like drug metabolism, DNA repair, and drug target interactions are critical determinants of chemotherapy efficacy.
  • Pharmacogenomic studies investigate how genetic variations influence these pathways, impacting drug action.

Purpose of the Study:

  • To highlight the crucial role of pharmacogenomics in predicting chemotherapy outcomes.
  • To identify promising pharmacogenomic markers for colorectal cancer treatment.
  • To emphasize the need for prospective clinical trials to validate retrospective findings.

Main Methods:

  • Review of pharmacogenomic studies focusing on genetic variants affecting drug metabolism, DNA repair, and drug targets.
  • Identification of candidate genes with predictive value for chemotherapy response and toxicity.
  • Discussion of the necessity for large-scale prospective clinical trials.

Main Results:

  • Promising pharmacogenomic candidates have been identified with predictive value for chemotherapy response and toxicity in colorectal cancers.
  • Retrospective analyses suggest a significant impact of these markers on response and survival.
  • Further validation is required to confirm these findings in prospective settings.

Conclusions:

  • Pharmacogenomic markers are crucial for predicting patient outcomes and tailoring chemotherapy regimens.
  • Prospective clinical trials are necessary to validate identified pharmacogenomic markers.
  • Confirmed markers, along with newly discovered ones, will enable personalized chemotherapy in the future.

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...